Filing Details

Accession Number:
0001387131-14-000686
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-26 19:31:38
Reporting Period:
2014-02-24
Filing Date:
2014-02-26
Accepted Time:
2014-02-26 19:31:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
25743 Therapeuticsmd Inc. TXMD Pharmaceutical Preparations (2834) 870233535
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1532230 Iv C.k. John Milligan 6800 Broken Sound Parkway Nw
3Rd Floor
Boca Raton FL 33487
President Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-02-24 8,300 $6.23 6,334,718 No 4 S Direct
Common Stock Disposition 2014-02-25 8,300 $6.16 6,326,418 No 4 S Direct
Common Stock Disposition 2014-02-26 8,400 $6.53 6,318,018 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The shares were sold pursuant to a 10b5-1 Sales Plan dated December 6,2013.
  2. The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $6.11 to $6.38, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $6.12 to $6.26, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $6.19 to $6.70, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.